Pnc Financial Services Group, Inc. Fate Therapeutics Inc Transaction History

Pnc Financial Services Group, Inc.

$148 Billion
Q4 2024

A detailed history of Pnc Financial Services Group, Inc. transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 447 shares of FATE stock, worth $558. This represents 0.0% of its overall portfolio holdings.

Number of Shares

447

Previous 434 3.0%

Holding current value

$558

Previous $1,000 100.0%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 07, 2025	BUY	$1.61 - $3.35 $20 - $43	13 Added 3.0%	447 $0
Q1 2024 May 10, 2024	SELL	$3.54 - $8.35 $354 - $835	-100 Reduced 18.73%	434 $3,000
Q4 2023 Feb 09, 2024	SELL	$1.65 - $3.94 $630 - $1,505	-382 Reduced 41.7%	534 $1,000
Q3 2023 Nov 13, 2023	SELL	$2.02 - $5.04 $4,242 - $10,584	-2,100 Reduced 69.63%	916 $1,000
Q2 2023 Aug 11, 2023	BUY	$4.76 - $6.59 $13,680 - $18,939	2,874 Added 2023.94%	3,016 $14,000
Q1 2023 May 15, 2023	SELL	$4.24 - $11.12 $34,407 - $90,238	-8,115 Reduced 98.28%	142 $0
Q4 2022 Feb 10, 2023	SELL	$9.86 - $23.83 $11,240 - $27,166	-1,140 Reduced 12.13%	8,257 $83,000
Q3 2022 Nov 10, 2022	SELL	$21.04 - $36.06 $19,945 - $34,184	-948 Reduced 9.16%	9,397 $210,000
Q2 2022 Aug 12, 2022	BUY	$17.78 - $42.39 $64,150 - $152,943	3,608 Added 53.55%	10,345 $256,000
Q1 2022 May 12, 2022	BUY	$29.67 - $60.28 $29,254 - $59,436	986 Added 17.14%	6,737 $261,000
Q4 2021 Feb 11, 2022	BUY	$47.84 - $64.34 $81,328 - $109,378	1,700 Added 41.96%	5,751 $336,000
Q3 2021 Nov 05, 2021	BUY	$59.27 - $95.73 $1,066 - $1,723	18 Added 0.45%	4,051 $240,000
Q2 2021 Aug 06, 2021	BUY	$67.25 - $92.52 $53,800 - $74,016	800 Added 24.74%	4,033 $350,000
Q1 2021 May 07, 2021	BUY	$72.16 - $117.4 $98,354 - $160,016	1,363 Added 72.89%	3,233 $266,000
Q4 2020 Feb 12, 2021	SELL	$38.09 - $100.95 $135,600 - $359,382	-3,560 Reduced 65.56%	1,870 $170,000
Q2 2020 Aug 07, 2020	SELL	$20.21 - $35.23 $7,477 - $13,035	-370 Reduced 6.38%	5,430 $186,000
Q1 2020 May 08, 2020	SELL	$17.28 - $31.88 $53,222 - $98,190	-3,080 Reduced 34.68%	5,800 $128,000
Q4 2019 Feb 07, 2020	SELL	$13.39 - $20.73 $33,475 - $51,825	-2,500 Reduced 21.97%	8,880 $173,000
Q3 2019 Nov 08, 2019	BUY	$15.47 - $22.5 $8,044 - $11,700	520 Added 4.79%	11,380 $176,000
Q1 2019 May 10, 2019	SELL	$13.15 - $18.71 $36,557 - $52,013	-2,780 Reduced 20.38%	10,860 $0
Q4 2018 Feb 08, 2019	BUY	$11.48 - $16.98 $48,904 - $72,334	4,260 Added 45.42%	13,640 $175,000
Q3 2018 Nov 09, 2018	SELL	$8.75 - $16.29 $9,975 - $18,570	-1,140 Reduced 10.84%	9,380 $0
Q2 2018 Aug 10, 2018	BUY	$9.16 - $13.48 $96,363 - $141,809	10,520 New	10,520 $0

Others Institutions Holding FATE

# of Institutions

168

Shares Held

113M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $121M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.

Account

Pnc Financial Services Group, Inc. Fate Therapeutics Inc Transaction History